Satish Garg
Concepts (662)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 103 | 2025 | 1291 | 17.850 |
Why?
| | Diabetes Mellitus, Type 1 | 153 | 2025 | 3715 | 17.080 |
Why?
| | Blood Glucose | 117 | 2025 | 2186 | 12.920 |
Why?
| | Blood Glucose Self-Monitoring | 70 | 2025 | 641 | 12.170 |
Why?
| | Insulin | 87 | 2025 | 2409 | 10.860 |
Why?
| | Diabetes Mellitus, Type 2 | 58 | 2025 | 2531 | 9.050 |
Why?
| | Diabetes Mellitus | 32 | 2024 | 1040 | 7.760 |
Why?
| | Hypoglycemia | 50 | 2023 | 445 | 6.730 |
Why?
| | Insulin Infusion Systems | 40 | 2025 | 394 | 6.210 |
Why?
| | Monitoring, Ambulatory | 17 | 2017 | 87 | 4.270 |
Why?
| | Myometrium | 9 | 2021 | 39 | 4.150 |
Why?
| | Buffaloes | 11 | 2021 | 13 | 4.140 |
Why?
| | Diabetic Ketoacidosis | 12 | 2024 | 201 | 3.590 |
Why?
| | Spermatozoa | 8 | 2024 | 94 | 3.520 |
Why?
| | Periodicals as Topic | 7 | 2020 | 211 | 3.170 |
Why?
| | Biosimilar Pharmaceuticals | 6 | 2020 | 23 | 3.110 |
Why?
| | Hyperglycemia | 17 | 2022 | 347 | 3.030 |
Why?
| | Insulin Glargine | 25 | 2022 | 84 | 3.020 |
Why?
| | Glycosides | 10 | 2024 | 36 | 2.940 |
Why?
| | Uterine Contraction | 8 | 2021 | 17 | 2.800 |
Why?
| | Pregnancy in Diabetics | 13 | 2023 | 123 | 2.690 |
Why?
| | Sperm Motility | 7 | 2024 | 32 | 2.580 |
Why?
| | Dog Diseases | 4 | 2021 | 64 | 2.480 |
Why?
| | Insulin Lispro | 14 | 2022 | 39 | 2.450 |
Why?
| | Insulin Aspart | 9 | 2020 | 27 | 2.390 |
Why?
| | Biomedical Technology | 5 | 2023 | 43 | 2.230 |
Why?
| | Mercury | 4 | 2025 | 41 | 2.180 |
Why?
| | Insulin, Long-Acting | 21 | 2022 | 63 | 2.150 |
Why?
| | Overweight | 4 | 2025 | 558 | 2.090 |
Why?
| | Humans | 211 | 2025 | 137585 | 2.080 |
Why?
| | Pancreas, Artificial | 5 | 2024 | 84 | 2.070 |
Why?
| | Cytokines | 7 | 2021 | 2085 | 2.030 |
Why?
| | Calcium | 9 | 2024 | 1199 | 1.940 |
Why?
| | Lead | 3 | 2024 | 64 | 1.770 |
Why?
| | Sperm Capacitation | 6 | 2021 | 12 | 1.640 |
Why?
| | Plant Extracts | 5 | 2019 | 202 | 1.610 |
Why?
| | Telemedicine | 6 | 2021 | 862 | 1.550 |
Why?
| | Antioxidants | 5 | 2020 | 584 | 1.510 |
Why?
| | Female | 118 | 2025 | 73304 | 1.480 |
Why?
| | Adult | 87 | 2025 | 37929 | 1.470 |
Why?
| | Male | 102 | 2025 | 67762 | 1.410 |
Why?
| | Glucagon-Like Peptides | 4 | 2025 | 58 | 1.400 |
Why?
| | Sepsis | 3 | 2023 | 617 | 1.370 |
Why?
| | Theileriasis | 2 | 2020 | 2 | 1.360 |
Why?
| | Insulins | 2 | 2024 | 37 | 1.360 |
Why?
| | Cattle | 9 | 2024 | 984 | 1.320 |
Why?
| | Animals | 52 | 2025 | 36940 | 1.320 |
Why?
| | Mite Infestations | 2 | 2020 | 8 | 1.290 |
Why?
| | Injections, Subcutaneous | 11 | 2021 | 157 | 1.290 |
Why?
| | rho-Associated Kinases | 3 | 2021 | 83 | 1.220 |
Why?
| | Vasoconstriction | 2 | 2022 | 202 | 1.210 |
Why?
| | Calcium Signaling | 3 | 2021 | 249 | 1.200 |
Why?
| | Postprandial Period | 5 | 2020 | 107 | 1.170 |
Why?
| | Middle Aged | 55 | 2025 | 33479 | 1.140 |
Why?
| | Pre-Eclampsia | 10 | 2023 | 190 | 1.140 |
Why?
| | Trace Elements | 2 | 2020 | 51 | 1.140 |
Why?
| | Obesity | 4 | 2025 | 2992 | 1.140 |
Why?
| | Diabetes Complications | 5 | 2020 | 227 | 1.100 |
Why?
| | Drug Therapy, Combination | 14 | 2021 | 1066 | 1.080 |
Why?
| | Trypanosomiasis | 2 | 2017 | 6 | 1.080 |
Why?
| | 3-Hydroxybutyric Acid | 3 | 2024 | 17 | 1.070 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2021 | 279 | 1.070 |
Why?
| | Insulin, Isophane | 6 | 2017 | 21 | 1.060 |
Why?
| | Dermatitis, Atopic | 2 | 2021 | 329 | 1.030 |
Why?
| | Rats, Wistar | 11 | 2020 | 455 | 1.020 |
Why?
| | Pandemics | 5 | 2022 | 1639 | 1.010 |
Why?
| | Drugs, Investigational | 2 | 2017 | 33 | 1.000 |
Why?
| | Protein Kinase C | 2 | 2018 | 261 | 0.990 |
Why?
| | Histamine | 2 | 2017 | 67 | 0.960 |
Why?
| | Glucagon-Like Peptide 1 | 4 | 2025 | 135 | 0.950 |
Why?
| | Acrosome Reaction | 2 | 2024 | 3 | 0.940 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 373 | 0.920 |
Why?
| | Coronavirus Infections | 2 | 2020 | 364 | 0.920 |
Why?
| | Acrosome | 1 | 2024 | 5 | 0.900 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 3 | 2013 | 47 | 0.890 |
Why?
| | Uterus | 6 | 2021 | 215 | 0.860 |
Why?
| | Monitoring, Physiologic | 6 | 2023 | 275 | 0.850 |
Why?
| | Biomedical Research | 8 | 2017 | 692 | 0.840 |
Why?
| | Treatment Outcome | 22 | 2025 | 10811 | 0.830 |
Why?
| | Diabetic Nephropathies | 2 | 2025 | 294 | 0.830 |
Why?
| | Reproducibility of Results | 14 | 2025 | 3284 | 0.820 |
Why?
| | Weight Loss | 4 | 2025 | 787 | 0.810 |
Why?
| | Angiotensin II | 1 | 2023 | 99 | 0.790 |
Why?
| | Spleen | 3 | 2020 | 514 | 0.780 |
Why?
| | Cross-Over Studies | 10 | 2020 | 564 | 0.770 |
Why?
| | Dinoprost | 2 | 2021 | 44 | 0.770 |
Why?
| | Receptor, Notch3 | 1 | 2022 | 5 | 0.760 |
Why?
| | Sulfones | 2 | 2020 | 110 | 0.750 |
Why?
| | Benzamides | 2 | 2020 | 216 | 0.740 |
Why?
| | Aorta | 2 | 2022 | 417 | 0.740 |
Why?
| | Registries | 8 | 2025 | 2035 | 0.730 |
Why?
| | Nifedipine | 6 | 2021 | 29 | 0.720 |
Why?
| | Intermediate Filament Proteins | 1 | 2021 | 57 | 0.720 |
Why?
| | Glucose | 6 | 2024 | 1020 | 0.710 |
Why?
| | Administration, Inhalation | 4 | 2018 | 688 | 0.710 |
Why?
| | Signal Transduction | 6 | 2024 | 5079 | 0.710 |
Why?
| | Pregnancy | 23 | 2023 | 6763 | 0.710 |
Why?
| | Dose-Response Relationship, Drug | 14 | 2020 | 2057 | 0.710 |
Why?
| | TRPC Cation Channels | 2 | 2021 | 14 | 0.710 |
Why?
| | Type C Phospholipases | 2 | 2018 | 74 | 0.700 |
Why?
| | Arterial Pressure | 1 | 2022 | 126 | 0.700 |
Why?
| | Insulin Antibodies | 2 | 2020 | 105 | 0.700 |
Why?
| | Trypanosoma | 2 | 2017 | 8 | 0.690 |
Why?
| | Dogs | 5 | 2021 | 413 | 0.690 |
Why?
| | Mitochondrial Membranes | 1 | 2021 | 39 | 0.690 |
Why?
| | Biopolymers | 1 | 2020 | 31 | 0.690 |
Why?
| | Endometritis | 2 | 2017 | 4 | 0.680 |
Why?
| | Theileria annulata | 1 | 2020 | 1 | 0.680 |
Why?
| | Chitosan | 1 | 2020 | 34 | 0.680 |
Why?
| | Calcium Channel Blockers | 6 | 2021 | 167 | 0.680 |
Why?
| | Protein Precursors | 1 | 2021 | 134 | 0.680 |
Why?
| | Young Adult | 25 | 2025 | 13209 | 0.680 |
Why?
| | Gelatin | 1 | 2020 | 52 | 0.670 |
Why?
| | Copper Sulfate | 1 | 2020 | 8 | 0.670 |
Why?
| | Diabetic Angiopathies | 6 | 2013 | 259 | 0.670 |
Why?
| | Exophthalmos | 1 | 2020 | 18 | 0.670 |
Why?
| | Betacoronavirus | 2 | 2020 | 270 | 0.670 |
Why?
| | Sodium-Glucose Transporter 1 | 2 | 2017 | 11 | 0.670 |
Why?
| | Mutagens | 1 | 2020 | 22 | 0.660 |
Why?
| | Selenium | 1 | 2020 | 43 | 0.660 |
Why?
| | Cattle Diseases | 1 | 2020 | 24 | 0.660 |
Why?
| | Sulfonylurea Compounds | 2 | 2018 | 48 | 0.660 |
Why?
| | Calcium Channels | 2 | 2018 | 159 | 0.660 |
Why?
| | Peste-des-petits-ruminants virus | 1 | 2019 | 1 | 0.650 |
Why?
| | Polyalthia | 1 | 2019 | 1 | 0.650 |
Why?
| | Oleic Acid | 1 | 2020 | 40 | 0.650 |
Why?
| | Patient Education as Topic | 6 | 2020 | 766 | 0.650 |
Why?
| | Newcastle disease virus | 1 | 2019 | 17 | 0.640 |
Why?
| | Infusions, Subcutaneous | 4 | 2016 | 23 | 0.640 |
Why?
| | Mites | 1 | 2019 | 7 | 0.640 |
Why?
| | Isoproterenol | 1 | 2020 | 113 | 0.630 |
Why?
| | Peroxidase | 2 | 2017 | 175 | 0.630 |
Why?
| | Down-Regulation | 1 | 2022 | 657 | 0.620 |
Why?
| | Potassium Channels | 1 | 2020 | 151 | 0.610 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 185 | 0.610 |
Why?
| | Aged | 25 | 2024 | 23961 | 0.610 |
Why?
| | Oxidative Stress | 4 | 2020 | 1317 | 0.600 |
Why?
| | Uterine Artery | 1 | 2019 | 79 | 0.590 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2111 | 0.590 |
Why?
| | Mercuric Chloride | 1 | 2018 | 2 | 0.590 |
Why?
| | Endocannabinoids | 2 | 2019 | 63 | 0.590 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2018 | 20 | 0.580 |
Why?
| | Biosensing Techniques | 2 | 2018 | 129 | 0.580 |
Why?
| | Voltage-Gated Sodium Channels | 1 | 2017 | 5 | 0.570 |
Why?
| | Tocolysis | 1 | 2017 | 4 | 0.570 |
Why?
| | Weight Gain | 6 | 2024 | 519 | 0.570 |
Why?
| | Wound Healing | 1 | 2020 | 331 | 0.570 |
Why?
| | Ethanolamines | 1 | 2017 | 17 | 0.570 |
Why?
| | Eucalyptus | 1 | 2017 | 8 | 0.560 |
Why?
| | KATP Channels | 1 | 2017 | 20 | 0.560 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2018 | 50 | 0.560 |
Why?
| | Vasodilation | 2 | 2019 | 499 | 0.560 |
Why?
| | Oxytocin | 2 | 2016 | 51 | 0.560 |
Why?
| | Adolescent | 30 | 2022 | 21513 | 0.550 |
Why?
| | Double-Blind Method | 9 | 2024 | 1993 | 0.550 |
Why?
| | Norepinephrine | 1 | 2018 | 204 | 0.550 |
Why?
| | Interleukins | 1 | 2019 | 250 | 0.550 |
Why?
| | Immunoglobulin E | 1 | 2019 | 342 | 0.550 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 927 | 0.540 |
Why?
| | Hydrogen Sulfide | 1 | 2017 | 44 | 0.540 |
Why?
| | Self Care | 4 | 2013 | 380 | 0.540 |
Why?
| | NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 3 | 0.530 |
Why?
| | Syringes | 3 | 2013 | 44 | 0.530 |
Why?
| | Coinfection | 1 | 2018 | 137 | 0.530 |
Why?
| | Cadmium | 1 | 2017 | 69 | 0.530 |
Why?
| | Therapies, Investigational | 1 | 2017 | 17 | 0.530 |
Why?
| | Hospitalization | 2 | 2024 | 2199 | 0.530 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 622 | 0.520 |
Why?
| | Inflammation Mediators | 1 | 2020 | 513 | 0.520 |
Why?
| | Mitochondria | 2 | 2021 | 948 | 0.520 |
Why?
| | Muscle Relaxation | 1 | 2016 | 19 | 0.520 |
Why?
| | Cholinesterases | 1 | 2016 | 10 | 0.510 |
Why?
| | Minerals | 1 | 2016 | 42 | 0.510 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 99 | 0.500 |
Why?
| | Calcium Channels, L-Type | 1 | 2017 | 118 | 0.490 |
Why?
| | Ambulatory Care Facilities | 2 | 2023 | 232 | 0.490 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2016 | 127 | 0.490 |
Why?
| | Insulin, Regular, Human | 3 | 2024 | 43 | 0.480 |
Why?
| | Body Mass Index | 8 | 2025 | 2389 | 0.480 |
Why?
| | Myocytes, Cardiac | 1 | 2020 | 526 | 0.470 |
Why?
| | Disposable Equipment | 2 | 2013 | 19 | 0.470 |
Why?
| | Vitamins | 1 | 2016 | 185 | 0.470 |
Why?
| | Consensus | 7 | 2023 | 683 | 0.460 |
Why?
| | United States | 17 | 2025 | 14841 | 0.460 |
Why?
| | Insulin Detemir | 5 | 2017 | 8 | 0.460 |
Why?
| | Gene Expression | 1 | 2020 | 1502 | 0.450 |
Why?
| | Drug Delivery Systems | 2 | 2018 | 365 | 0.450 |
Why?
| | Prospective Studies | 14 | 2025 | 7604 | 0.440 |
Why?
| | Biomarkers | 12 | 2025 | 4149 | 0.440 |
Why?
| | Rats | 7 | 2020 | 5647 | 0.440 |
Why?
| | Drug Administration Schedule | 8 | 2017 | 786 | 0.430 |
Why?
| | Withania | 1 | 2013 | 6 | 0.430 |
Why?
| | Glucagon | 2 | 2022 | 109 | 0.430 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2013 | 45 | 0.420 |
Why?
| | Antiviral Agents | 1 | 2019 | 744 | 0.420 |
Why?
| | Extracellular Fluid | 1 | 2013 | 31 | 0.410 |
Why?
| | Glucosides | 3 | 2019 | 44 | 0.410 |
Why?
| | Nervous System Diseases | 1 | 2016 | 266 | 0.410 |
Why?
| | Chlorpyrifos | 1 | 2013 | 7 | 0.400 |
Why?
| | Retrospective Studies | 10 | 2025 | 15657 | 0.400 |
Why?
| | Benzhydryl Compounds | 3 | 2019 | 73 | 0.400 |
Why?
| | Membrane Potential, Mitochondrial | 3 | 2024 | 72 | 0.400 |
Why?
| | History, 21st Century | 3 | 2020 | 213 | 0.400 |
Why?
| | Microsomes, Liver | 1 | 2013 | 86 | 0.390 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1046 | 0.390 |
Why?
| | Portal Vein | 1 | 2013 | 120 | 0.390 |
Why?
| | Time Factors | 12 | 2021 | 6828 | 0.380 |
Why?
| | Arsenic | 1 | 2013 | 64 | 0.380 |
Why?
| | Pregnancy Outcome | 3 | 2023 | 416 | 0.370 |
Why?
| | Pyrazines | 1 | 2013 | 90 | 0.370 |
Why?
| | Tocolytic Agents | 2 | 2017 | 16 | 0.370 |
Why?
| | Triazoles | 1 | 2013 | 147 | 0.360 |
Why?
| | Patient Preference | 1 | 2013 | 191 | 0.360 |
Why?
| | Needles | 1 | 2011 | 59 | 0.360 |
Why?
| | Ascorbic Acid | 1 | 2013 | 177 | 0.360 |
Why?
| | Prevalence | 8 | 2020 | 2734 | 0.360 |
Why?
| | Goats | 2 | 2021 | 27 | 0.350 |
Why?
| | Adrenergic beta-Agonists | 2 | 2017 | 134 | 0.340 |
Why?
| | Clinical Trials as Topic | 7 | 2022 | 1050 | 0.340 |
Why?
| | History, 20th Century | 3 | 2019 | 325 | 0.330 |
Why?
| | Blood Chemical Analysis | 2 | 2017 | 99 | 0.330 |
Why?
| | Acetylcholine | 3 | 2019 | 185 | 0.320 |
Why?
| | Water Pollutants, Chemical | 1 | 2013 | 215 | 0.320 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2022 | 173 | 0.320 |
Why?
| | DNA Damage | 2 | 2024 | 420 | 0.320 |
Why?
| | Calibration | 3 | 2018 | 146 | 0.320 |
Why?
| | China | 4 | 2020 | 217 | 0.310 |
Why?
| | Organometallic Compounds | 2 | 2024 | 111 | 0.310 |
Why?
| | Pregnancy Trimester, First | 3 | 2020 | 140 | 0.310 |
Why?
| | 4-Aminopyridine | 2 | 2020 | 24 | 0.310 |
Why?
| | Intention to Treat Analysis | 3 | 2017 | 73 | 0.310 |
Why?
| | Health Care Costs | 4 | 2016 | 398 | 0.310 |
Why?
| | Reference Values | 6 | 2023 | 816 | 0.300 |
Why?
| | Plant Leaves | 3 | 2019 | 147 | 0.300 |
Why?
| | alpha-Tocopherol | 2 | 2020 | 33 | 0.290 |
Why?
| | Prediabetic State | 1 | 2011 | 253 | 0.290 |
Why?
| | Research Design | 6 | 2015 | 1139 | 0.290 |
Why?
| | Computer Systems | 2 | 2018 | 45 | 0.290 |
Why?
| | Animals, Newborn | 2 | 2020 | 844 | 0.280 |
Why?
| | Veratridine | 2 | 2017 | 6 | 0.280 |
Why?
| | Blood Pressure | 4 | 2025 | 1786 | 0.270 |
Why?
| | Software | 3 | 2013 | 665 | 0.270 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1809 | 0.270 |
Why?
| | Sodium-Glucose Transport Proteins | 2 | 2017 | 2 | 0.260 |
Why?
| | Equipment Design | 4 | 2010 | 522 | 0.260 |
Why?
| | Child | 11 | 2022 | 21935 | 0.250 |
Why?
| | United States Food and Drug Administration | 3 | 2018 | 208 | 0.250 |
Why?
| | Nitric Oxide | 3 | 2022 | 915 | 0.250 |
Why?
| | Journal Impact Factor | 2 | 2020 | 28 | 0.250 |
Why?
| | Vasodilator Agents | 2 | 2019 | 331 | 0.250 |
Why?
| | Risk Factors | 8 | 2024 | 10388 | 0.250 |
Why?
| | Ruthenium Red | 2 | 2016 | 7 | 0.240 |
Why?
| | Blotting, Western | 3 | 2017 | 1226 | 0.240 |
Why?
| | Diabetic Retinopathy | 2 | 2005 | 189 | 0.240 |
Why?
| | Albuminuria | 3 | 2017 | 185 | 0.240 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1242 | 0.240 |
Why?
| | Hypertension | 4 | 2011 | 1295 | 0.240 |
Why?
| | Tissue Culture Techniques | 2 | 2017 | 78 | 0.240 |
Why?
| | Copper | 2 | 2016 | 104 | 0.240 |
Why?
| | Lipoproteins | 2 | 2019 | 168 | 0.230 |
Why?
| | Phenylephrine | 2 | 2016 | 75 | 0.230 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 2 | 2017 | 11 | 0.230 |
Why?
| | Algorithms | 5 | 2018 | 1704 | 0.230 |
Why?
| | Glomerular Filtration Rate | 3 | 2025 | 746 | 0.230 |
Why?
| | Fasting | 1 | 2006 | 281 | 0.230 |
Why?
| | Exercise | 2 | 2014 | 2057 | 0.230 |
Why?
| | Body Weight | 7 | 2020 | 985 | 0.230 |
Why?
| | Semen Analysis | 1 | 2024 | 14 | 0.230 |
Why?
| | Calcinosis | 4 | 2010 | 235 | 0.220 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 37 | 0.220 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 9 | 0.220 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 14 | 0.220 |
Why?
| | Phosphorylation | 2 | 2020 | 1759 | 0.220 |
Why?
| | Pyrazoles | 2 | 2018 | 423 | 0.220 |
Why?
| | Drug Approval | 1 | 2024 | 88 | 0.210 |
Why?
| | Uridine Diphosphate | 1 | 2023 | 3 | 0.210 |
Why?
| | Cyclic AMP | 1 | 2024 | 234 | 0.210 |
Why?
| | Equipment Failure | 2 | 2018 | 108 | 0.200 |
Why?
| | Mass Screening | 1 | 2011 | 1287 | 0.200 |
Why?
| | Reproduction | 1 | 2025 | 204 | 0.200 |
Why?
| | Dietary Supplements | 2 | 2018 | 561 | 0.200 |
Why?
| | Endocrinology | 2 | 2016 | 79 | 0.200 |
Why?
| | Receptors, Glucagon | 1 | 2022 | 27 | 0.190 |
Why?
| | Vitamin D-Binding Protein | 2 | 2020 | 15 | 0.190 |
Why?
| | Aged, 80 and over | 3 | 2022 | 7635 | 0.190 |
Why?
| | Safety | 3 | 2009 | 338 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1477 | 0.190 |
Why?
| | Ketosis | 1 | 2021 | 12 | 0.180 |
Why?
| | Mice | 5 | 2023 | 17787 | 0.180 |
Why?
| | Reference Standards | 4 | 2017 | 186 | 0.180 |
Why?
| | Testis | 2 | 2025 | 151 | 0.180 |
Why?
| | Illinois | 1 | 2021 | 43 | 0.180 |
Why?
| | Immunization, Passive | 1 | 2021 | 90 | 0.180 |
Why?
| | Mobile Applications | 2 | 2021 | 183 | 0.180 |
Why?
| | Patient Isolation | 1 | 2021 | 19 | 0.180 |
Why?
| | New York City | 1 | 2021 | 85 | 0.180 |
Why?
| | Los Angeles | 1 | 2021 | 76 | 0.180 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2020 | 52 | 0.170 |
Why?
| | Child, Preschool | 5 | 2022 | 11074 | 0.170 |
Why?
| | Micronucleus Tests | 1 | 2020 | 6 | 0.170 |
Why?
| | Comet Assay | 1 | 2020 | 16 | 0.170 |
Why?
| | Antigens, Viral | 1 | 2021 | 178 | 0.170 |
Why?
| | Patient Satisfaction | 3 | 2015 | 660 | 0.170 |
Why?
| | Skin Diseases, Parasitic | 1 | 2020 | 3 | 0.170 |
Why?
| | Interleukin-13 | 1 | 2021 | 149 | 0.170 |
Why?
| | Progesterone | 2 | 2019 | 254 | 0.170 |
Why?
| | Uncoupling Protein 2 | 1 | 2020 | 8 | 0.170 |
Why?
| | Chromium | 1 | 2020 | 15 | 0.160 |
Why?
| | Cardiotoxicity | 1 | 2020 | 26 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2025 | 579 | 0.160 |
Why?
| | Incidence | 3 | 2017 | 2804 | 0.160 |
Why?
| | Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 1 | 0.160 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1587 | 0.160 |
Why?
| | Curcumin | 1 | 2020 | 29 | 0.160 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 165 | 0.160 |
Why?
| | Income | 1 | 2021 | 202 | 0.160 |
Why?
| | Glycemic Index | 2 | 2009 | 27 | 0.160 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4295 | 0.160 |
Why?
| | Cyclooxygenase 1 | 1 | 2019 | 27 | 0.160 |
Why?
| | Vero Cells | 1 | 2019 | 69 | 0.160 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 12 | 0.160 |
Why?
| | Virus Internalization | 1 | 2019 | 49 | 0.160 |
Why?
| | Lipid Peroxidation | 1 | 2020 | 153 | 0.160 |
Why?
| | Haptoglobins | 1 | 2019 | 53 | 0.160 |
Why?
| | Canagliflozin | 1 | 2019 | 10 | 0.150 |
Why?
| | Tyrosine | 1 | 2020 | 222 | 0.150 |
Why?
| | Area Under Curve | 3 | 2015 | 314 | 0.150 |
Why?
| | Host-Parasite Interactions | 1 | 2020 | 114 | 0.150 |
Why?
| | Adamantane | 1 | 2019 | 18 | 0.150 |
Why?
| | Diabetes, Gestational | 1 | 2023 | 318 | 0.150 |
Why?
| | Immunity, Cellular | 2 | 2018 | 268 | 0.150 |
Why?
| | Dipeptides | 1 | 2019 | 50 | 0.150 |
Why?
| | Ion Channels | 1 | 2019 | 133 | 0.150 |
Why?
| | TRPV Cation Channels | 1 | 2019 | 40 | 0.150 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 316 | 0.150 |
Why?
| | California | 1 | 2020 | 431 | 0.150 |
Why?
| | Congresses as Topic | 2 | 2020 | 233 | 0.150 |
Why?
| | Vitamin D | 2 | 2020 | 397 | 0.150 |
Why?
| | Methyldopa | 1 | 2018 | 7 | 0.150 |
Why?
| | Meals | 1 | 2020 | 125 | 0.150 |
Why?
| | Patient Care Planning | 1 | 2019 | 157 | 0.140 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2018 | 45 | 0.140 |
Why?
| | Organ Culture Techniques | 1 | 2018 | 156 | 0.140 |
Why?
| | Self Efficacy | 1 | 2002 | 396 | 0.140 |
Why?
| | Aminooxyacetic Acid | 1 | 2017 | 1 | 0.140 |
Why?
| | Sodium Channel Agonists | 1 | 2017 | 1 | 0.140 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2017 | 4 | 0.140 |
Why?
| | Sensitivity and Specificity | 4 | 2009 | 1946 | 0.140 |
Why?
| | International Agencies | 1 | 2017 | 35 | 0.140 |
Why?
| | Injections | 1 | 2018 | 183 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 545 | 0.140 |
Why?
| | Hemoglobin A | 1 | 2017 | 21 | 0.140 |
Why?
| | Malondialdehyde | 1 | 2017 | 29 | 0.140 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 45 | 0.140 |
Why?
| | Serum Amyloid A Protein | 1 | 2017 | 33 | 0.140 |
Why?
| | Equivalence Trials as Topic | 1 | 2017 | 9 | 0.140 |
Why?
| | Administration, Oral | 2 | 2017 | 816 | 0.140 |
Why?
| | Glyburide | 1 | 2017 | 32 | 0.140 |
Why?
| | Analysis of Variance | 1 | 2020 | 1316 | 0.140 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 32 | 0.140 |
Why?
| | Methanol | 1 | 2017 | 38 | 0.140 |
Why?
| | Alkynes | 1 | 2017 | 56 | 0.140 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 79 | 0.140 |
Why?
| | Protein Carbonylation | 1 | 2017 | 54 | 0.140 |
Why?
| | Biomechanical Phenomena | 1 | 2021 | 810 | 0.140 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 181 | 0.140 |
Why?
| | Solvents | 1 | 2017 | 109 | 0.140 |
Why?
| | Adipokines | 1 | 2017 | 49 | 0.140 |
Why?
| | Data Interpretation, Statistical | 1 | 2019 | 363 | 0.130 |
Why?
| | Propanolamines | 1 | 2017 | 96 | 0.130 |
Why?
| | Immunization | 1 | 2019 | 411 | 0.130 |
Why?
| | Islet Amyloid Polypeptide | 3 | 2013 | 47 | 0.130 |
Why?
| | Phytotherapy | 1 | 2017 | 83 | 0.130 |
Why?
| | Patient Dropouts | 1 | 2017 | 67 | 0.130 |
Why?
| | Patient Compliance | 2 | 2013 | 581 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2021 | 625 | 0.130 |
Why?
| | Anniversaries and Special Events | 1 | 2017 | 15 | 0.130 |
Why?
| | Longitudinal Studies | 6 | 2020 | 2844 | 0.130 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 178 | 0.130 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2017 | 159 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 804 | 0.130 |
Why?
| | Furans | 1 | 2016 | 24 | 0.130 |
Why?
| | Computer-Aided Design | 1 | 2017 | 43 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2018 | 271 | 0.130 |
Why?
| | Uric Acid | 1 | 2018 | 163 | 0.130 |
Why?
| | Up-Regulation | 1 | 2020 | 843 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2018 | 218 | 0.130 |
Why?
| | Glycine | 1 | 2017 | 176 | 0.130 |
Why?
| | Indicators and Reagents | 1 | 2016 | 106 | 0.130 |
Why?
| | Cell Survival | 1 | 2020 | 1120 | 0.130 |
Why?
| | Oleaceae | 1 | 2016 | 1 | 0.130 |
Why?
| | Coronary Artery Disease | 3 | 2010 | 698 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1236 | 0.130 |
Why?
| | Sympathomimetics | 1 | 2016 | 21 | 0.130 |
Why?
| | In Vitro Techniques | 2 | 2016 | 1092 | 0.130 |
Why?
| | Piperidines | 1 | 2018 | 206 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 298 | 0.130 |
Why?
| | Antihypertensive Agents | 3 | 2012 | 494 | 0.130 |
Why?
| | Cysteine | 1 | 2017 | 204 | 0.130 |
Why?
| | Eating | 3 | 2009 | 380 | 0.130 |
Why?
| | Lung | 1 | 2009 | 4060 | 0.130 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1289 | 0.130 |
Why?
| | Pilot Projects | 2 | 2018 | 1710 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1622 | 0.120 |
Why?
| | Aniline Compounds | 1 | 2016 | 102 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 496 | 0.120 |
Why?
| | Drug Hypersensitivity | 1 | 2017 | 90 | 0.120 |
Why?
| | Amyloid | 2 | 2007 | 87 | 0.120 |
Why?
| | Leptin | 2 | 2017 | 236 | 0.120 |
Why?
| | Membrane Potentials | 1 | 2016 | 284 | 0.120 |
Why?
| | Forecasting | 2 | 2016 | 389 | 0.120 |
Why?
| | Drug Design | 1 | 2017 | 167 | 0.120 |
Why?
| | Moringa oleifera | 1 | 2015 | 3 | 0.120 |
Why?
| | Estradiol | 1 | 2019 | 521 | 0.120 |
Why?
| | Incretins | 1 | 2015 | 22 | 0.120 |
Why?
| | Interleukin-10 | 1 | 2017 | 302 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2016 | 283 | 0.120 |
Why?
| | Imidazoles | 1 | 2016 | 238 | 0.120 |
Why?
| | Postnatal Care | 1 | 2016 | 71 | 0.120 |
Why?
| | Vascular Stiffness | 1 | 2021 | 494 | 0.120 |
Why?
| | Toll-Like Receptor 4 | 1 | 2017 | 273 | 0.120 |
Why?
| | RNA, Messenger | 1 | 2023 | 2833 | 0.120 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2013 | 253 | 0.120 |
Why?
| | Early Diagnosis | 2 | 2015 | 242 | 0.110 |
Why?
| | Cells, Cultured | 2 | 2020 | 4193 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 628 | 0.110 |
Why?
| | Materials Testing | 2 | 2017 | 356 | 0.110 |
Why?
| | Cholesterol, HDL | 1 | 2015 | 203 | 0.110 |
Why?
| | Estrenes | 1 | 2014 | 16 | 0.110 |
Why?
| | Self-Management | 1 | 2017 | 176 | 0.110 |
Why?
| | Vitamin D Deficiency | 2 | 2020 | 186 | 0.110 |
Why?
| | Pyrrolidinones | 1 | 2014 | 28 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2019 | 3556 | 0.110 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.110 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 8 | 0.110 |
Why?
| | Allylamine | 1 | 2013 | 8 | 0.110 |
Why?
| | Bromocriptine | 1 | 2013 | 30 | 0.110 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 24 | 0.110 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 89 | 0.110 |
Why?
| | Inflammation | 1 | 2005 | 2837 | 0.110 |
Why?
| | Colorado | 2 | 2020 | 4565 | 0.110 |
Why?
| | Staining and Labeling | 1 | 2014 | 150 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2017 | 408 | 0.100 |
Why?
| | Catecholamines | 1 | 2013 | 98 | 0.100 |
Why?
| | Prenatal Care | 1 | 2016 | 294 | 0.100 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 450 | 0.100 |
Why?
| | Escherichia coli | 1 | 2017 | 815 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2015 | 236 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1738 | 0.100 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 105 | 0.100 |
Why?
| | Toxicity Tests, Subacute | 1 | 2013 | 1 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 840 | 0.100 |
Why?
| | Coronary Disease | 2 | 2007 | 385 | 0.100 |
Why?
| | Age Factors | 2 | 2019 | 3295 | 0.100 |
Why?
| | Sitagliptin Phosphate | 1 | 2013 | 33 | 0.100 |
Why?
| | Autoantibodies | 2 | 2018 | 1496 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2016 | 451 | 0.100 |
Why?
| | Menopause | 1 | 2016 | 320 | 0.100 |
Why?
| | Quality of Life | 5 | 2016 | 2892 | 0.100 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 1060 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2013 | 137 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 181 | 0.100 |
Why?
| | Insecticides | 1 | 2013 | 38 | 0.100 |
Why?
| | Leadership | 1 | 2017 | 388 | 0.100 |
Why?
| | Patient Selection | 2 | 2009 | 696 | 0.100 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2013 | 64 | 0.100 |
Why?
| | Circadian Rhythm | 4 | 2015 | 468 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1996 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2607 | 0.090 |
Why?
| | Zinc | 1 | 2015 | 297 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2016 | 2475 | 0.090 |
Why?
| | Drinking Water | 1 | 2013 | 84 | 0.090 |
Why?
| | Self Administration | 1 | 2011 | 123 | 0.090 |
Why?
| | Internet | 1 | 2016 | 655 | 0.090 |
Why?
| | Carotenoids | 1 | 2011 | 43 | 0.090 |
Why?
| | Swine | 1 | 2013 | 775 | 0.090 |
Why?
| | Managed Care Programs | 1 | 2011 | 135 | 0.090 |
Why?
| | Cohort Studies | 4 | 2019 | 5742 | 0.080 |
Why?
| | Regression Analysis | 2 | 2010 | 1024 | 0.080 |
Why?
| | Eicosapentaenoic Acid | 1 | 2010 | 39 | 0.080 |
Why?
| | Home Care Services | 1 | 2013 | 257 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 350 | 0.080 |
Why?
| | Metformin | 1 | 2013 | 331 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2014 | 5778 | 0.080 |
Why?
| | Drug Combinations | 1 | 2010 | 343 | 0.080 |
Why?
| | Decision Making | 2 | 2013 | 900 | 0.080 |
Why?
| | Carcinogens | 1 | 2009 | 125 | 0.070 |
Why?
| | Physicians | 2 | 2017 | 910 | 0.070 |
Why?
| | Vital Capacity | 1 | 2009 | 311 | 0.070 |
Why?
| | Disease Progression | 3 | 2012 | 2757 | 0.070 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 42 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2486 | 0.070 |
Why?
| | Cross-Sectional Studies | 4 | 2015 | 5472 | 0.070 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 531 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 890 | 0.070 |
Why?
| | Norway | 2 | 2019 | 43 | 0.070 |
Why?
| | C-Reactive Protein | 2 | 2013 | 410 | 0.070 |
Why?
| | Medication Adherence | 1 | 2011 | 467 | 0.070 |
Why?
| | Drug Costs | 1 | 2008 | 106 | 0.070 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 76 | 0.070 |
Why?
| | Sheep | 1 | 2010 | 856 | 0.070 |
Why?
| | Infusion Pumps, Implantable | 2 | 2004 | 25 | 0.070 |
Why?
| | Nebulizers and Vaporizers | 1 | 2007 | 86 | 0.070 |
Why?
| | Risk Management | 2 | 2019 | 93 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 85 | 0.060 |
Why?
| | Australia | 2 | 2019 | 315 | 0.060 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 201 | 0.060 |
Why?
| | Societies, Medical | 1 | 2010 | 820 | 0.060 |
Why?
| | Infant | 1 | 2020 | 9465 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 499 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 806 | 0.060 |
Why?
| | Alprostadil | 1 | 2005 | 32 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1171 | 0.060 |
Why?
| | Immunity, Humoral | 2 | 2016 | 116 | 0.060 |
Why?
| | Barium Compounds | 1 | 2004 | 8 | 0.060 |
Why?
| | Terbutaline | 1 | 2004 | 8 | 0.060 |
Why?
| | Spermatogenesis | 1 | 2025 | 67 | 0.060 |
Why?
| | Organ Size | 2 | 2016 | 477 | 0.060 |
Why?
| | Potassium Chloride | 1 | 2004 | 38 | 0.060 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2004 | 21 | 0.060 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2004 | 45 | 0.060 |
Why?
| | Hyperlipidemias | 1 | 2005 | 120 | 0.060 |
Why?
| | Dinoprostone | 1 | 2005 | 191 | 0.060 |
Why?
| | Automation | 1 | 2004 | 95 | 0.050 |
Why?
| | Albuterol | 1 | 2004 | 110 | 0.050 |
Why?
| | Pulmonary Artery | 1 | 2010 | 1086 | 0.050 |
Why?
| | Capillaries | 1 | 2004 | 108 | 0.050 |
Why?
| | Chlorides | 1 | 2004 | 136 | 0.050 |
Why?
| | Homeostasis | 1 | 2007 | 621 | 0.050 |
Why?
| | Modems | 1 | 2003 | 1 | 0.050 |
Why?
| | Fetal Macrosomia | 1 | 2003 | 62 | 0.050 |
Why?
| | Glycation End Products, Advanced | 1 | 2023 | 82 | 0.050 |
Why?
| | Transaminases | 1 | 2022 | 24 | 0.050 |
Why?
| | Food | 1 | 2004 | 164 | 0.050 |
Why?
| | Primary Health Care | 1 | 2013 | 1738 | 0.050 |
Why?
| | Congenital Abnormalities | 1 | 2003 | 92 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2003 | 213 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2022 | 116 | 0.050 |
Why?
| | Educational Status | 1 | 2004 | 470 | 0.050 |
Why?
| | Ketone Bodies | 1 | 2021 | 14 | 0.050 |
Why?
| | Brain | 1 | 2013 | 2668 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5131 | 0.050 |
Why?
| | Preconception Care | 1 | 2002 | 43 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2002 | 61 | 0.040 |
Why?
| | Age of Onset | 1 | 2003 | 518 | 0.040 |
Why?
| | Breath Tests | 1 | 2021 | 87 | 0.040 |
Why?
| | Ketones | 1 | 2021 | 49 | 0.040 |
Why?
| | Prognosis | 2 | 2020 | 4030 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 106 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 445 | 0.040 |
Why?
| | Pregnancy Trimester, Second | 1 | 2020 | 80 | 0.040 |
Why?
| | Learning | 1 | 2004 | 409 | 0.040 |
Why?
| | Self Concept | 1 | 2002 | 253 | 0.040 |
Why?
| | Birth Weight | 1 | 2003 | 516 | 0.040 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2020 | 41 | 0.040 |
Why?
| | Gestational Age | 1 | 2003 | 910 | 0.040 |
Why?
| | Skin | 1 | 2004 | 752 | 0.040 |
Why?
| | Vascular Resistance | 1 | 2021 | 375 | 0.040 |
Why?
| | Polyunsaturated Alkamides | 1 | 2019 | 8 | 0.040 |
Why?
| | Capsaicin | 1 | 2019 | 26 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 340 | 0.040 |
Why?
| | Data Accuracy | 1 | 2019 | 65 | 0.040 |
Why?
| | Arachidonic Acids | 1 | 2019 | 62 | 0.040 |
Why?
| | Databases, Factual | 1 | 2004 | 1357 | 0.040 |
Why?
| | Immunoblotting | 1 | 2019 | 308 | 0.040 |
Why?
| | Internationality | 1 | 2019 | 155 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 171 | 0.040 |
Why?
| | Sleep | 2 | 2015 | 755 | 0.040 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2017 | 6 | 0.040 |
Why?
| | Sodium | 1 | 2019 | 217 | 0.040 |
Why?
| | Resistin | 1 | 2017 | 11 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 310 | 0.030 |
Why?
| | Lipocalin-2 | 1 | 2017 | 79 | 0.030 |
Why?
| | North America | 1 | 2018 | 313 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2017 | 19 | 0.030 |
Why?
| | Survival Rate | 1 | 2022 | 1972 | 0.030 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2017 | 70 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 665 | 0.030 |
Why?
| | Seminiferous Tubules | 1 | 2016 | 13 | 0.030 |
Why?
| | Semen | 1 | 2016 | 18 | 0.030 |
Why?
| | Hypersensitivity, Delayed | 1 | 2016 | 28 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 560 | 0.030 |
Why?
| | Drug Resistance | 1 | 2017 | 169 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 601 | 0.030 |
Why?
| | Models, Economic | 1 | 2016 | 58 | 0.030 |
Why?
| | Cost Savings | 1 | 2016 | 84 | 0.030 |
Why?
| | Edema | 1 | 2016 | 130 | 0.030 |
Why?
| | Research Personnel | 1 | 2017 | 173 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 548 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 660 | 0.030 |
Why?
| | Flowers | 1 | 2016 | 64 | 0.030 |
Why?
| | Antibodies, Bacterial | 1 | 2016 | 146 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2017 | 218 | 0.030 |
Why?
| | Adiponectin | 1 | 2017 | 244 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1468 | 0.030 |
Why?
| | Equipment and Supplies | 1 | 2015 | 42 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2015 | 132 | 0.030 |
Why?
| | Body Burden | 1 | 2015 | 8 | 0.030 |
Why?
| | C-Peptide | 1 | 2015 | 163 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 455 | 0.030 |
Why?
| | Salmonella typhimurium | 1 | 2016 | 183 | 0.030 |
Why?
| | Communication | 1 | 2020 | 879 | 0.030 |
Why?
| | Neoplasms | 1 | 2009 | 2671 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2017 | 512 | 0.030 |
Why?
| | Genotype | 2 | 2010 | 1916 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1943 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2017 | 413 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 591 | 0.030 |
Why?
| | Prenatal Diagnosis | 1 | 2015 | 201 | 0.030 |
Why?
| | Data Display | 1 | 2013 | 21 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 951 | 0.030 |
Why?
| | E-Selectin | 1 | 2013 | 57 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 852 | 0.030 |
Why?
| | Chemokine CXCL10 | 1 | 2013 | 39 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2020 | 986 | 0.020 |
Why?
| | Testosterone | 1 | 2016 | 409 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2167 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2020 | 1069 | 0.020 |
Why?
| | Risk | 1 | 2015 | 912 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 307 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2016 | 778 | 0.020 |
Why?
| | Bone and Bones | 1 | 2015 | 317 | 0.020 |
Why?
| | Tetraethylammonium | 1 | 2011 | 16 | 0.020 |
Why?
| | beta Carotene | 1 | 2011 | 21 | 0.020 |
Why?
| | Vitamin A | 1 | 2011 | 58 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3196 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Calcium Chloride | 1 | 2010 | 12 | 0.020 |
Why?
| | Expert Testimony | 1 | 2010 | 39 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2010 | 32 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2011 | 170 | 0.020 |
Why?
| | Nitrites | 1 | 2010 | 84 | 0.020 |
Why?
| | Cholesterol | 1 | 2012 | 410 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 847 | 0.020 |
Why?
| | Intracellular Space | 1 | 2010 | 68 | 0.020 |
Why?
| | Extracellular Space | 1 | 2010 | 119 | 0.020 |
Why?
| | Potassium | 1 | 2010 | 147 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2010 | 139 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2010 | 240 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 976 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2828 | 0.020 |
Why?
| | Serotonin | 1 | 2010 | 323 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 9 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 52 | 0.020 |
Why?
| | Long-Term Care | 1 | 2007 | 107 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2007 | 99 | 0.020 |
Why?
| | Fatty Acids | 1 | 2010 | 443 | 0.020 |
Why?
| | Models, Biological | 1 | 2013 | 1783 | 0.010 |
Why?
| | Peptides | 1 | 2011 | 985 | 0.010 |
Why?
| | Fructosamine | 1 | 2005 | 15 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2031 | 0.010 |
Why?
| | Hemoglobins | 1 | 2007 | 353 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 392 | 0.010 |
Why?
| | Sex Distribution | 1 | 2005 | 375 | 0.010 |
Why?
| | Hemoglobinuria | 1 | 2003 | 3 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 2003 | 2691 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2003 | 762 | 0.010 |
Why?
| | Logistic Models | 1 | 2003 | 2074 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2003 | 1208 | 0.010 |
Why?
|
|
Garg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|